文献速递创伤与烧伤重症综合管理与镇静镇痛

严重创伤后外泌体microRNA:在骨髓功能障碍中的作用

Exosomal microRNA following severe trauma: Role in bone marrow dysfunction.
PubMed 文献 · J Trauma Acute Care Surg · 2023-12-28
一句话结论严重创伤患者血浆外泌体中60个miRNA显著下调、3个上调,其中12个直接调控造血,且存在性别二态性。

本研究基于前瞻性队列,纳入15例髋部和/或股骨骨折且损伤严重度评分≥15的创伤患者,以8例择期全髋关节置换术患者为手术对照,分离血浆外泌体并直接定量miRNA。结果显示,与全髋关节置换术对照组相比,创伤组血浆外泌体有60个miRNA显著下调、3个上调(p<0.05),其中12个下调miRNA直接参与造血调控。男性创伤患者外泌体有150个miRNA下调,而女性创伤患者仅4个下调、2个上调(p<0.05),提示性别二态性。作者认为,理解miRNA的性别二态性表达有助于认识创伤后全身炎症、免疫失调和骨髓功能障碍的性别差异,并有助于未来更精准的潜在治疗策略。

要点

  • 严重创伤(髋部和/或股骨骨折、损伤严重度评分≥15)患者血浆外泌体中60个miRNA显著下调、3个上调(与全髋关节置换术对照相比,p<0.05)。
  • 12个下调的miRNA直接参与造血调控,可能与创伤后骨髓功能障碍相关。
  • 男性创伤患者外泌体有150个miRNA下调,女性创伤患者仅4个下调、2个上调(p<0.05),显示miRNA表达的性别二态性。
  • 创伤组平均损伤严重度评分为23,与全髋关节置换术组在年龄和性别分布上无差异。
  • 作者认为,理解性别二态性miRNA表达可为创伤后全身炎症、免疫失调和骨髓功能障碍的性别差异提供新见解,并有助于未来更精准的潜在治疗策略。

适用人群与场景

  • 创伤患者:髋部和/或股骨骨折,损伤严重度评分≥15,来自前瞻性队列研究(n=15;7男,8女)。
  • 手术对照:择期全髋关节置换术患者(n=8;4男,4女)。

研究设计与关键结果

  • 研究类型:前瞻性队列研究(创伤患者)与手术对照(择期全髋关节置换术)比较。
  • 样本量:创伤患者n=15(7男,8女),全髋关节置换术对照n=8(4男,4女)。
  • 人群:髋部和/或股骨骨折且损伤严重度评分≥15的创伤患者;对照组为择期全髋关节置换术患者。
  • 主要终点:创伤组与全髋关节置换术组血浆外泌体miRNA表达差异。创伤组有60个miRNA显著下调、3个miRNA显著上调(p<0.05);下调的miRNA中12个直接参与造血调控。
  • 性别亚组:男性创伤组较男性全髋关节置换术组有150个miRNA下调(p<0.05);女性创伤组较女性全髋关节置换术组仅4个miRNA下调、2个miRNA上调(p<0.05)。
  • 基线:创伤组与全髋关节置换术组年龄和性别分布无差异;创伤组平均损伤严重度评分为23。

证据类型、等级与局限

  • 证据类型:前瞻性队列研究(预后与流行病学)。
  • 证据等级:Level III(预后与流行病学)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,理解创伤后血浆外泌体miRNA的性别二态性表达,可为认识创伤后全身炎症、免疫系统失调和骨髓功能障碍的性别差异提供新见解,并有助于未来更精准的潜在治疗策略。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

INTRODUCTION: Severe trauma disrupts bone marrow function and is associated with persistent anemia and altered hematopoiesis. Previously, plasma-derived exosomes isolated after trauma have been shown to suppress in vitro bone marrow function. However, the cargo contained in these vesicles has not been examined. We hypothesized that trauma plasma-derived exosomes exhibit microRNA (miRNA) changes that impact bone marrow function after severe injury.

METHODS: Plasma was collected from a prospective cohort study of trauma patients (n = 15; 7 males, 8 females) with hip and/or femur fractures and an Injury Severity Score of ≥15; elective total hip arthroplasty (THA) patients (n = 8; 4 males, 4 females) served as operative controls. Exosomes were isolated from plasma with the Invitrogen Total Exosome Isolation Kit (Thermo Fisher Scientific, Waltham, MA), and RNA was isolated using a miRNeasy Mini Kit (Qiagen, Hilden, Germany). Direct quantification of miRNA was performed by NanoString Technologies on a human miRNA gene panel and analyzed with nSolver with significance defined as p < 0.05.

RESULTS: There were no differences in age or sex distribution between trauma and THA groups; the average Injury Severity Score was 23. Trauma plasma-derived exosomes had 60 miRNA identities that were significantly downregulated and 3 miRNAs that were upregulated when compared with THA ( p < 0.05). Twelve of the downregulated miRNAs have a direct role in hematopoiesis regulation. Furthermore, male trauma plasma-derived exosomes demonstrated downregulation of 150 miRNAs compared with male THA ( p < 0.05). Female trauma plasma-derived exosomes demonstrated downregulation of only four miRNAs and upregulation of two miRNAs compared with female THA ( p < 0.05).

CONCLUSION: We observed downregulation of 12 miRNAs linked to hematopoiesis along with sexual dimorphism in miRNA expression from plasma-derived exosomes following severe trauma. Understanding sexually dimorphic miRNA expression provides new insight into sex-based changes in postinjury systemic inflammation, immune system dysregulation, and bone marrow dysfunction and will aid us in more precise future potential therapeutic strategies.

LEVEL OF EVIDENCE: Prognostic and Epidemiological; Level III.

来源:J Trauma Acute Care Surg,查看原文。版权归原作者所有。

参考来源

  1. Munley JA, Willis ML, Gillies GS, et al. Exosomal microRNA following severe trauma: Role in bone marrow dysfunction. J Trauma Acute Care Surg. 2023. PMID: 38151766. doi:10.1097/TA.0000000000004225

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。